Ginolis, a Finnish company founded in 2010, is a leading provider of robot-based automation solutions used world-wide to manufacture a variety of medical disposables and point-of-care tests such as Covid-19 tests. Today Ginolis is a multi-national company with approx. 100 employees in Finland, Estonia, the UK, China and the Unites states, with customers in Europe, North America and China.
“Over the last 11 years, we have developed a strong foundation and built well-renowned customer relationships within our industry. As a current partner to CELLINK, we are well acquainted with the culture, the technology, and innovation-driven agenda as well as their high ambitions. We look forward to becoming part of CELLINK’s bio convergence vision and bringing our expertise, products and workflow to a wider audience,” says Ginolis’ CEO Teijo Fabritius.
CELLINK is a bioink company revolutionizing bioprinting and are the global leader for designing and commercializing bioprinting technologies. Their innovations enable to 3D print organs and tissue for applications that span industries, from pharmaceutical to cosmetics.
”Ginolis is another fantastic example of the great engineering know-how coming from Finland’s Oulu region. It has been great to work together with such a strong and capable co-investor such as Verso Capital as well” commented Petri Laine, Innovestor Ventures partner and Ginolis board member.
For more information
Partner, Innovestor Ventures
+358 400 909 447
Innovestor is a Nordic early-stage venture capital investor, that also offers direct co-investment syndication and corporate venturing services. Currently the firm manages one of the largest private venture-backed portfolios in the Nordics, consisting of over 100 high-tech companies in multiple fields of technology. Their aim is to be the best home for future new Nordic success stories. At its core, they boost the success and growth of portfolio companies by giving access to capital, know-how, and networks by utilizing their unique ecosystem of co-investors and partners.